November 2000 — BioSpace.com, Inc. is the most heavily trafficked business-to-business life sciences site on the Internet today. The company has selected R&D Manage as the tool to budget and forecast their P&L by project and by organization.
September 2000 — GeneSoft, Inc. a South San Francisco company focused on pharmaceuticals that modulate gene expression, has subscribed to R&D Manage with Quick Books to budget and forecast R&D expenses.
August 2000 — Collabra Pharma, Inc., a drug development company based in South San Francisco, has chosen R&D Manage™ with Quick Books to manage their budgeting and tracking of R&D expenses.
2001
October 2001 — NEUROGENETICS, Inc. has subscribed to R&D Manage software and services. Neurogenetics is a San Diego-based emerging biopharmaceutical company focused on the development of therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, including Parkinson's disease (PD), Huntington’s disease (HD), stroke, amyotrophic lateral sclerosis (ALS), epilepsy and chronic pain.
October 2001 — PHARMOS Corporation has subscribed to R&D Manage software and services. Additionally, R&D Manage will support consolidation between the Israel and US divisions. Pharmos Corporation is a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central and peripheral nervous systems, and ophthalmologic, cardiovascular and inflammation-related indications.
October 2001 — NEUROGEN Corporation has acquired a global license for using R&D Manage software and services. Neurogen is a leader in both the discovery and development of new drug candidates and in the development and integration of new drug discovery technologies, most notably its AIDD (Accelerated Intelligent Drug Discovery) system.
July 2001 — Hyseq, Inc. and Zyomyx have recently subscribed to R&D Manage software and services. Hyseq, located in Sunnyvale, California, applies its genomics platform to find and develop biopharmaceuticals products. Zyomyx, located in Hayward, California, is developing a new generation of biochips which will enable miniaturized, ultrahigh-throughput protein analyses to bridge the technology gap in the discovery process for the biological and life sciences industry.
June 2001 — NeoTherapeutics, Inc. and Metabolex, Inc. have recently joined our user community. NeoTherapeutics, located in Irvine, California, is a development-stage biopharmaceutical company engaged in the discovery and advancement of novel therapeutic agents intended to treat neurological and psychiatric diseases and conditions. Metabolex discovers and develops new drugs for type 2 diabetes and brings to market novel drugs with distinct and complementary modes of action, to address the full range of defects underlying diabetes. Both companies will be using R&D Manage on a subscription mode and will first use the system to create their 2002 budgets.
March 2001 — Valentis, Inc, is taking the discoveries of genomics research and applying proprietary delivery systems to create therapeutics with improved safety, efficacy or dosing convenience. Valentis has what is believed to be the broadest array of technologies and intellectual property for the delivery of biopharmaceuticals in the industry. R&D Manage will be integrated with Platinum and the local time reporting system. The company has centers in three locations: The Woodlands, Texas, which houses the team focused on preclinical Research & Development; London, England, where PolyMASC operates as a wholly-owned subsidiary and focuses on polymer-based delivery; and Burlingame, California, which is the company headquarters as well as the center for manufacturing and clinical development. R&D Manage will be rolled out to the US locations in April 2001.
February 2001 — Sunesis Pharmaceuticals is applying a revolutionary new approach to drug discovery that is based on a novel chemical methodology combined with critical insights into the nature of molecular recognition between natural macromolecules and their substrates or ligands. Sunesis will be using R&D Manage™ and the electronic integration with Quick Books. Cytokinetics Inc. is focused on the complementary missions of drug discovery and the commercialization of novel cellular bioinformatics technologies. We are excited to integrate R&D Manage™ with the General Ledger of Microsoft Dynamics accounting system.
February 2001 — Intrabiotics Pharmaceuticals Inc, is a biopharmaceutical company developing novel antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases, including those related to the phenomenon of multi-drug resistant microbes and the infectious complications of neutropenia. R&D Manage™ will be integrated with MAS90 and local time reporting system.
2002
December 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded with additional currency exchange, planning and reporting capabilities.
August 2002 — NPS Pharmaceuticals, Inc. located in Salt Lake City, Utah has subscribed to R&D Logic software solution and services. NPS Pharmaceuticals was founded in 1986 and is engaged in the discovery and development of novel, small molecule drugs and recombinant peptides that address a variety of important diseases. With operations in both US and Canada, NPSP will start using the R&D Manage software by developing a detailed global budget across the various organizations.
August 2002 — Discovery Partners International, Inc. located in San Diego, California has subscribed to R&D Logic software solution and services. Discovery Partners has become a leader in drug discovery collaborations by offering integrated services and products that span the drug discovery continuum including target characterization, high throughput screening, lead generation, lead optimization, high throughput synthesis automation, and gene expression analysis. With operations in both US and Europe, DPI will start using the R&D Manage software by developing a detailed global budget for the entire corporation.
July 2002 — Guilford Pharmaceuticals, Inc. located in Baltimore, Maryland has subscribed to R&D Logic software solution and services. With implementation efforts already under way, we are looking forward to integrating the R&D Manage software within a unified platform for budgeting and forecasting of the Guilford financials.
July 2002 — Novacea, Inc. located in South San Francisco, California has subscribed to R&D Logic software solution and services. Novacea is a rapidly growing drug development company that has the exclusive worldwide rights to the Oregon Health & Science University (OHSU) technology for dose and a method of use of calcitriol and its analogs, potentially providing a major breakthrough in the treatment of cancer. R&D Manage will be first used to create a long range plan of the Company financials, with an emphasis on clinical trial costs.
April 2002 — CellGate, Inc. located in Sunnyvale, California has subscribed to R&D Logic software solution and services. CellGate is a pioneer in the application and development of transporter molecules to deliver novel medicines into cells and through tissues.
January 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded with additional reporting capabilities.
January 2002 — The newest release of R&D Manage product has been rolled out to all current customers. The software functionality has been expanded with additional direct and indirect project costing capabilities.
January 2002 — The newest release of R&D Manage product has been rolled out to all customers. The software functionality has been expanded to include budgeting based on standard rates; existing functions have been improved and enhanced as well.
2003
November 2003 — EPIX Medical, Inc. located in Cambridge, Massachusetts has selected R&D Logic software solution and services for managing their corporate and project financials. EPIX Medical (NASDAQ: EPIX)is a specialty pharmaceutical company and a worldwide leader in the discovery and development of targeted MRI contrast agents for the diagnosis and clinical management of disease.
November 2003 — Cytokinetics and Novacea have signed up as beta customers of our latest product under development, R&D Time. This new product facilitates capturing the employees' monthly effort by project along with providing electronic approvals, alerts and graphical analysis of project resources utilization across the corporation.
September 2003 — The R&D Manage 3.0 release has been rolled out to all customers. This major release introduces an enhanced reporting mechanism, a complete rewrite of most standard reports along with a new technology to seamlessly download reports to Excel. Customer response has been extremely enthusiastic.
August 2003 — BioMedicines, Inc. located in Emeryville, California has selected R&D Logic software solution and services for managing their corporate and project financials. BioMedicines specializes in developing and systematically generating new uses for clinical-stag drugs purchased or licensed from major pharmaceutical companies.
August 2003 — In an effort to better serve our customers, R&D Logic organizes quarterly webinars to discuss topics of common interest. The first such webinars are being held this month to present new features of the latest product release. Watch for announcements of future topics!
August 2003 — R&D Logic has adopted J2EE as its new strategic technical platform. New products under development are switched to the new technology. R&D Logic is also pleased to announce the hiring of Mr. Wayne Kidd to spearhead the implementation of the J2EE architecture and platform. Mr. Kidd, well known by the Java community, brings a wealth of technical expertise and product development experience to our efforts.
2004
December 2004 — R&D P&L complements R&D Manage and supports the calculation, formatting, viewing (including drill-down) and direct download to Excel of a Company's Profit & Loss Statement. The module also automates allocations (Facility, G&A, &D, Cost of Goods Sold, etc.) required to produce a complete P&L statement.
December 2004 — R&D Manage 3.1 release has been rolled out to all customer. This new release incorporates functions in project resources and financials tracking, as well as new reporting tools.
December 2004 — R&D P&L has been enhanced with additional flexibility for defining financial reporting criteria as well as new publishing features for easy distribution. There are currently seven different companies that have purchased this application and are successfully using it for producing and distributing monthly and pro-forma financials.
October 2004 — Avigen, Inc. located in Alameda, California has selected R&D Manage and R&D Time software to support corporate and project planning and tracking activities. Avigen (NASDAQ: AVGN) is a leader in the development of gene therapy products to treat serious, chronic diseases.
February 2004 — R&D Time 1.0 release has been commercially launched to two sites. The response from customers has been overwhelmingly positive and enthusiastic.
January 2004 — Epix, who currently uses R&D Manage for their corporate budgeting and tracking, has decided to expand their usage of R&D Logic products and include R&D Time, a software tool specifically developed to collect project efforts by employee. R&D Time will replace the current time collection system.
2005
December 2005 — Valentis, Inc., located in Burlingame, California, has selected R&D Time to replace in-house time and attendance system and complete the R&D Logic enterprise suite that has been in used for the past four years. Valentis is a biotechnology company engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market.
August 2005 — NeuroMolecular Pharmaceuticals, Inc., located in Emeryville, California has selected R&D Manage™ and P&L platform to support project portfolio and corporate planning and tracking business processes. NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders.
August 2005 — Avidia, Inc. located in Mountain View, California, has selected R&D Manage, R&D Time and R&D P&L to support corporate strategic and operational planning as well as monthly collecting and tracking. Avidia is focused on developing a new class of therapeutic proteins for treatments in areas including autoimmunity, inflammation and oncology.
April 2005 — R&D Logic announces new product features for its R&D Time Module setting a new standard in integrating planning and resource time tracking software offerings.
2006
December 2006 — Five Príme Therapeutics, Inc., located in San Francisco, California, has selected R&D Logic software for planning and tracking, and time collection. FivePríme Therapeutics, Inc. is a pre-clinical stage biotech company discovering and developing innovative protein and antibody therapeutics. FivePríme is developing treatments for cancer and diabetes and multiple leads in metabolic and immunologic diseases, oncology and regenerative medicine.
November 2006 — Macroflux Corporation, located in Mountain View, California, has opted to use the R&D Logic complete enterprise solution for planning and tracking, and time collection. Macroflux is a spin-out of ALZA Corporation (a subsidiary of Johnson & Johnson). The Macroflux system is based on a small patch and applicator that is intended to provide a needle-free solution for transdermal delivery of therapeutic proteins, peptides and vaccines. It is designed to combine painless and convenient drug administration with rapid delivery and high bioavailability.
October 2006 — SGX Pharmaceuticals Inc., located in San Diego, California, has decided to use R&D Logic enterprise solution to support FP&A company-wide processes. SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.
September 2006 — Alnylam Pharmaceuticals Inc., located in Cambridge, Massachusetts, has selected R&D Manage, R&D Time and R&D P&L to support corporate strategic and financial planning as well as monthly tracking and analysis. Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi.
August 2006 — Momenta Pharmaceuticals Inc., located in Cambridge, Massachusetts, has selected R&D Logic suite of software to support planning and tracking, time collection and corporate analysis and financial reporting. Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars (polysaccharides) for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes.
July 2006 — InterMune Inc., located in Brisbane, California, has opted to use R&D Logic software to support Project Time collection as well Time off collecting and tracking, our latest addition to the enterprise solution. In addition, InterMune will be using software capabilities to track and analyze resource utilization by project and program. InterMune is a publicly traded biotech company focused on developing and commercializing innovative therapies in hepatology and pulmonology.
June 2006 — Titan Pharmaceuticals Inc., located in South San Francisco, California, has selected the full R&D Logic suite of software to support corporate planning and tracking, time collection, and financial reporting. Titan is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders.
2007
December 2007 — Savient Pharmaceuticals, located in East Brunswick, New Jersey, has selected R&D Logic software for corporate planning, collecting and tracking, and financial reporting. Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.
December 2007 — Tercica, Inc., located in Brisbane, California, has chosen R&D Logic software for corporate planning, collecting and tracking, and financial reporting. Tercica is a biopharmaceutical company working to develop and commercialize therapeutics for growth and other endocrine disorders.
October 2007 — Catalyst Biosciences, located in South San Francisco, California, has opted to use R&D Logic software for time collection efforts, while planning and tracking project resources. Catalyst Biosciences is a leading biotechnology company focused on developing proteases as a therapeutic platform for inflammation, cardiovascular, and angiogenesis-based disorders.
August 2007 — Via Pharmaceuticals, Inc., located in San Francisco, California, has selected R&D Logic enterprise software for financial planning and analysis, consolidated reporting as well as for project time collection and project portfolio specific planning and tracking. VIA is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease.
June 2007 — Kalypsys, Inc., located in San Diego, California, has chosen R&D Logic software for tracking and planning project resources and time effort. Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developing breakthrough therapies for some of the world's most widespread diseases including cardiovascular/metabolic diseases, pain/inflammation and oncology.
2008
December 2008 — Ambrx, located in La Jolla, California, has subscribed to R&D Time software service to collect, track and report project effort. Special emphasys will be put on tracking effort by collaborator. Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics.
October 2008 — NTI, located in Emeryville, California, has chosen R&D Logic budgeting software to create the next corporate plan. Neurobiological Technologies, Inc. is a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates.
April 2008 — With R&D SELECT, customers can choose from pre-configured scenarios or build their own!
2009
November 2009 — MacroGenics, Inc., located in Rockville, Maryland, has subscribed to R&D Logic software services to manage world-wide corporate planning and tracking,budgeting and forecasting, and financial reporting. MacroGenics'mission is to discover, develop and deliver to patients novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases.
November 2009 — Facet Biotech, located in Redwood City, California, has subscribed to R&D Time software services to manage corporate budgeting and forecasting, time collection, and project FTE reporting. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc. Combining expertise in antibody engineering with a disciplined, biology-driven research approach, Facet Biotech is dedicated to advancing our current pipeline of four clinical-stage products and leveraging our research and development capabilities to identify and develop new drugs.
October 2009 — Inviragen, Inc.located in Fort Collins, Colorado, has subscribed to R&D Time software services to manage world-wide time collection and grant reporting. Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide.
June 2009 — KaloBios Pharmaceuticals, located in South San Francisco, California, has subscribed to R&D Time software services to manage corporate time collection and project FTE reporting.KaloBios uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics.
May 2009 — Medivation, Inc., located in San Francisco, California, has subscribed to R&D Logic software services for planning and tracking expenses and resources at the corporate and project portfolio levels as well as for collecting and tracking R&D project time to collaborators and to internal management. Medivation is is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs.
April 2009 — Portola Pharmaceuticals located in South San Francisco, California, has subscribed to R&D Time software service to manage all corporate time collection, financial reporting, and project FTE reporting. Portola is discovering and developing novel therapeutics to meet patient needs in cardiovascular, inflammation, and oncology indications.
April 2009 — Nevro Corporation, located in Palo Alto, California, has subscribed to R&D Manage software service for planning and tracking expenses and resources at the corporate and project portfolio levels. Nevro is a medical device company developing novel neuromodulation therapies for multiple indications.
February 2009 — Portola Pharmaceuticals located in South San Francisco, California, has subscribed to R&D Time software service to manage all corporate time collection, financial reporting, and project FTE reporting. Portola is discovering and developing novel therapeutics to meet patient needs in cardiovascular, inflammation, and oncology indications.
2020-today 2010-2019 2000-2009